Christopher Boone

Former VP, Global Head of Health Economics and Outcomes Research

Christopher P. Boone, Ph.D. is an accomplished global executive, strategist, professor, social scientist, and data technologist with a passion for reinventing and transforming healthcare and life sciences companies utilizing enterprise data & analytics capabilities to drive value creation. Chris has a career-long history as a dynamic, innovative, and transformative data & analytics executive, thought leader, and a public voice on the power of real-world evidence, health informatics, and enterprise data & analytics and its ability to radically transform the global health care system into a learning health care system.

Chris served as the Vice President, Global Head of Health Economics and Outcomes Research at AbbVie. He is also an adjunct assistant professor of health administration at the New York University’s Robert F. Wagner Graduate School of Public Service, an active board member of several influential organizations, and a co-founder of a few start-up companies. Prior to AbbVie, he served in two different roles at Pfizer: (1) the Vice President and Head of Global Medical Epidemiology and Big Data Analysis, and (2) the Vice President and Global Head of Real-World Data and Analytics.

Chris has been recognized as an inducted member of the Executive Leadership Council (2023), Top 50 Leadership Excellence Award by the National Diversity and Leadership Council (2023, 2021), a Global Top 100 Innovator in Data & Analytics (2020, 2019), an Emerging Pharma Leader by Pharmaceutical Executive (2018), and a Top 40 Under 40 Leaders in Health (2017) by the National Minority Quality Forum.

Chris holds appointments to some of the most influential national committees focused on health data and patient centricity, including the Board of Governors for PCORI, the Board of Directors for Global Medical Response, the Board of Directors for Stewards of Change Institute, the Advisory Board of Mango Sciences, the Advisory Board of TrialBee, the American Heart Association’s Clinical Studies Expert Panel, the Global Liver Institute for Liver Health Equity Advisory Board, and the Strategic Advisory Committee for the Texas Biomedical Institute.